Last reviewed · How we verify
BP31510 in combination with chemotherapy
BP31510 in combination with chemotherapy is a Small molecule drug developed by BPGbio. It is currently in Phase 1 development.
At a glance
| Generic name | BP31510 in combination with chemotherapy |
|---|---|
| Sponsor | BPGbio |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BP31510 in combination with chemotherapy CI brief — competitive landscape report
- BP31510 in combination with chemotherapy updates RSS · CI watch RSS
- BPGbio portfolio CI
Frequently asked questions about BP31510 in combination with chemotherapy
What is BP31510 in combination with chemotherapy?
BP31510 in combination with chemotherapy is a Small molecule drug developed by BPGbio.
Who makes BP31510 in combination with chemotherapy?
BP31510 in combination with chemotherapy is developed by BPGbio (see full BPGbio pipeline at /company/bpgbio).
What development phase is BP31510 in combination with chemotherapy in?
BP31510 in combination with chemotherapy is in Phase 1.